199106-13-3

199106-13-3 structure

Name: MJ33
Chemical Name: lithium,[1-hexadecoxy-3-(2,2,2-trifluoroethoxy)propan-2-yl] methyl phosphate
CAS Number: 199106-13-3
Molecular Formula: C₂₂H₄₄F₃O₇P
Molecular Weight: 498.48300
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phospholipase
Create Date: 2017-03-27 23:44:24
Modify Date: 2025-08-25 16:40:24
MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6[1]. MJ33 has a critical effect on inflammatory brain damage[2].

Name	lithium,[1-hexadecoxy-3-(2,2,2-trifluoroethoxy)propan-2-yl] methyl phosphate
Synonyms	IN1224 MJ33 lithium salt MJ33 mj33 lithium salt

Description	MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6[1]. MJ33 has a critical effect on inflammatory brain damage[2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phospholipase Research Areas >> Inflammation/Immunology
In Vitro	MJ33, a transition-state analog competitive inhibitor of PLA2, inhibits the degradation of dipalmitoylphosphatidylcholine (DPPC) by ∼50% in both the whole lung and isolated alveolar type 2 cells. In vitro measurement of PLA2 activity in homogenate of lungs or isolated type 2 cells is markedly inhibited by MJ33 when assays at pH 4.0 in Ca2+-free medium but has no effect on Ca2+-dependent PLA2 activity at pH 8.5[3].
In Vivo	MJ33 (0.5 μM/kg ; by tail vein, at 24 h before MCAO) significantly blocks the increase IL-1β, IL-17 and IL-23 in rats stimulated by Prdx6 siRNA treatment[2]. Compared with the Prdx6 siRNA group, combined exposure to Prdx6 siRNA and MJ33 significantly downregulates the mRNA and protein expression of NF-κB, iNOS and COX-2[2]. Animal Model: Adult male Sprague-Dawley rats weighing 270-310 g (middle cerebral artery occlusion (MCAO) group) [2] Dosage: 0.5 μM/kg Administration: By tail vein, at 24 h before MCAO Result: Significantly blocked the increase IL-1β, IL-17 and IL-23 in rats stimulated by Prdx6 siRNA treatment.
References	[1]. Shanshan Y, et al. Phospholipase A2 of Peroxiredoxin 6 Plays a Critical Role in Cerebral Ischemia/Reperfusion Inflammatory Injury. Front Cell Neurosci. 2017 Apr 5;11:99. [2]. Moawad AR, et al. Deficiency of peroxiredoxin 6 or inhibition of its phospholipase A2 activity impair the in vitro sperm fertilizing competence in mice. Sci Rep. 2017 Oct 11;7(1):12994. [3]. Fisher AB, et al. Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2. J Lipid Res. 2005 Jun;46(6):1248-56.

Boiling Point	522.7ºC at 760 mmHg
Molecular Formula	C₂₂H₄₄F₃O₇P
Molecular Weight	498.48300
Flash Point	269.9ºC
Exact Mass	498.29100
PSA	86.86000
LogP	7.63340
Vapour Pressure	2.5E-12mmHg at 25°C
Storage condition	2-8°C

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Safety Phrases	S22
RIDADR	NONH for all modes of transport

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

199106-13-3	1135306-36-3
1007476-63-2	2086299-69-4
2086299-97-8	2098092-36-3
1669415-62-6	1563531-88-3
109812-54-6	51486-05-6
2309456-13-9	2097011-67-9
454183-26-7